583 692
the present meta-analysis may be of great value for certain
subgroups of patients.
In conclusion, the work by Dahm et al
[6]clearly reveals
the existing limitations and shortcomings of current
medical LUTS research and treatment. This may be a good
reason to reconsider our current approach to the way we
design studies evaluating medical treatment for male LUTS.
By setting up trials with relevant endpoints and adequate
follow-up, results may translate into clear benefit for our
patients.
Conflicts of interest:
The authors have nothing to disclose.
References
[1]
Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118–40.
[2]
Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, dou- ble-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;59:342–52.
[3]
Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system inmen with storage and voiding lower urinary tract symptoms: results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol 2015;67: 262–70.
[4]
Chapple CR, Roehrborn CG, McVary K, Ilo D, Henneges C, Viktrup L. Effect of tadalafil on male lower urinary tract symptoms: an inte- grated analysis of storage and voiding international prostate symp- tom subscores from four randomised controlled trials. Eur Urol 2015;67:114–22.
[5]
Fullhase C, Chapple C, Cornu JN, et al. Systematic review of combi- nation drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64:228–43.
[6]
Dahm P, Brasure M, MacDonald R, et al. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta- analysis. Eur Urol 2017;71:570–81.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 8 2 – 5 8 3
583